TY - JOUR
T1 - Predictors of adverse outcome among patients with hypertension and coronary artery disease
AU - Pepine, Carl J.
AU - Kowey, Peter R.
AU - Kupfer, Stuart
AU - Kolloch, Rainer E.
AU - Benetos, Athanase
AU - Mancia, Giuseppe
AU - Coca, Antonio
AU - Cooper-Dehoff, Rhonda M.
AU - Handberg, Eileen
AU - Gaxiola, Efrain
AU - Sleight, Peter
AU - Conti, C. Richard
AU - Hewkin, Ann C.
AU - Tavazzi, Luigi
PY - 2006/2/7
Y1 - 2006/2/7
N2 - OBJECTIVES: We sought to determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD). BACKGROUND: Factors leading to adverse outcomes in hypertensive patients with CAD are poorly understood. The INternational VErapamil-trandolapril STudy (INVEST) compared outcomes in hypertensive patients with CAD that were assigned randomly to either a verapamil sustained-release (SR)- or an atenolol-based strategy for blood pressure (BP) control. Trandolapril and hydrochlorothiazide were used as added agents. During follow-up (61,835 patient-years), BP control and the primary outcome (death, nonfatal myocardial infarction, and nonfatal stroke) were not different between strategies. METHODS: We investigated risk for adverse outcome associated with baseline factors, follow-up BP, and drug treatments using Cox modeling. RESULTS: Previous heart failure (adjusted hazard ratio [HR] 1.96), as well as diabetes (HR 1.77), increased age (HR 1.63), U.S. residency (HR 1.61), renal impairment (HR 1.50), stroke/transient ischemic attack (HR 1.43), smoking (HR 1.41), myocardial infarction (HR 1.34), peripheral vascular disease (HR 1.27), and revascularization (HR 1.15) predicted increased risk. Follow-up systolic BP
AB - OBJECTIVES: We sought to determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD). BACKGROUND: Factors leading to adverse outcomes in hypertensive patients with CAD are poorly understood. The INternational VErapamil-trandolapril STudy (INVEST) compared outcomes in hypertensive patients with CAD that were assigned randomly to either a verapamil sustained-release (SR)- or an atenolol-based strategy for blood pressure (BP) control. Trandolapril and hydrochlorothiazide were used as added agents. During follow-up (61,835 patient-years), BP control and the primary outcome (death, nonfatal myocardial infarction, and nonfatal stroke) were not different between strategies. METHODS: We investigated risk for adverse outcome associated with baseline factors, follow-up BP, and drug treatments using Cox modeling. RESULTS: Previous heart failure (adjusted hazard ratio [HR] 1.96), as well as diabetes (HR 1.77), increased age (HR 1.63), U.S. residency (HR 1.61), renal impairment (HR 1.50), stroke/transient ischemic attack (HR 1.43), smoking (HR 1.41), myocardial infarction (HR 1.34), peripheral vascular disease (HR 1.27), and revascularization (HR 1.15) predicted increased risk. Follow-up systolic BP
UR - http://www.scopus.com/inward/record.url?scp=31644438866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31644438866&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2005.09.031
DO - 10.1016/j.jacc.2005.09.031
M3 - Article
C2 - 16458134
AN - SCOPUS:31644438866
VL - 47
SP - 547
EP - 551
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
SN - 0735-1097
IS - 3
ER -